Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Core Viewpoint - Alto Neuroscience, Inc. has completed patient enrollment in its Phase 2 proof-of-concept clinical trial for ALTO-101, targeting cognitive impairment associated with schizophrenia [1] Company Summary - Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders [1] - The company is evaluating ALTO-101, a transdermal phosphodiesterase-4 (PDE4) inhibitor, in its clinical trial [1] Industry Context - The trial aims to address cognitive impairment associated with schizophrenia, a significant area of need in neuropsychiatric treatment [1]